Shots:
- The companies collaborated to evaluate ruxolitinib in combination with CK0804 in patients with MF and plan to initiate a P-Ib study. Incyte will fund the study while operationalized by Cellenkos
- Cellenkos to receive $20M as licensing fee, ~$294.5M as development, regulatory and commercialization milestones along with royalties on sales of therapies, if approved. Incyte has an exclusive option to acquire sole rights to develop and commercialize CK0804 in benign and malignant hematology indications
- Following the exercising the global license option, Incyte to lead all activities and costs associated with research, development, and commercialization of the program
Click here to read full press release/ article | Ref: Businessiwre | Image: Businesswire
The post Incyte Collaborates with Cellenkos for CK0804 to Treat Myelofibrosis first appeared on PharmaShots.
